# Acute Sinusitis Market

> Acute Sinusitis Market Research Report Information By Treatment (Saline Nasal Spray, Nasal Corticosteroids, Decongestants, OTC Pain Relievers, Allergy Shots and Antibiotics), By End-Users (Hospitals & Clinics and Research Centers), By Diagnosis (Nasal Endoscopy, Imaging Test, Laboratory Test and Allergy Testing), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.92%
- **2024:** $ 2.32 Billion
- **2025:** $ 2.48 Billion
- **2035:** $ 4.84 Billion
- **Key Players:** GlaxoSmithKline (GB), Sanofi (FR), Bayer (DE), Merck & Co. (US), AstraZeneca (GB), Novartis (CH), Teva Pharmaceutical Industries (IL), Johnson & Johnson (US), AbbVie (US)

**Report ID:** MRFR/HC/4371-CR · **Pages:** 126 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/acute-sinusitis-market-5827

---

## Market Summary

## **Global Acute Sinusitis Market Overview**

Acute Sinusitis Market Size was valued at USD 2.15 Billion in 2023. The acute sinusitis market industry is projected to grow from USD 2.31 Billion in 2024 to USD 3.961 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.92% during the forecast period (2024 - 2032). Since acute sinusitis affects a large portion of the population worldwide, governments and businesses are collaborating to address the issue and offer better solutions, and government and business investments in technological advancements are raising the likelihood of a market expansion.

Additionally, rising demand for over-the-counter medicines and treatments, such as nasal corticosteroids and nasal sprays, is a significant market driver that is projected to propel market expansion in the years to come.

Source Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

In May 2023, Zocdoc, the preeminent healthcare marketplace, made an announcement regarding its expansion to encompass urgent treatment. This development will assist patients in conveniently locating and scheduling both in-person and virtual treatments for over twelve thousand insurance types and over two hundred specialties. Through Zocdoc, it is now possible to schedule appointments online at over two hundred urgent care centers in twenty-two states. In fact, Urgent Care is one of the care categories on Zocdoc that is expanding the quickest, for both providers and patients.

Appointment requests for urgent care facilities increased by an average of 80% per month in 2023, while the number of new Zocdoc urgent care facilities increased by nearly 40% per month. Urgent care clinics are visited by Zocdoc patients seeking treatment for infections such as sinusitis.

In May 2023, the supplemental new drug application (sNDA) submitted by the pharmaceutical company Optinose for the approval of XHANCE, a treatment for chronic rhinosinusitis, was accepted for review by the U.S. Food and Drug Administration (FDA). A revolutionary drug-device combination, the XHANCE (fluticasone propionate) nasal spray combines the most popular nasal anti-inflammatory medication with the cutting-edge Exhalation Delivery System (EDS). The EDS was created to provide a novel method of medication delivery, specifically into the difficult-to-reach sinuses and sinonasal drainage systems.

The Prescription Drug User Fee Act (PDUFA) target objective date for the sNDA filing of the ReOpen Program is December 16, 2023. This date is based on the findings of two Phase 3 clinical studies involving patients diagnosed with chronic sinusitis.

## **Acute Sinusitis Market Trends**

Since children's sinuses are smaller and less formed, adults are more likely to acquire acute sinusitis than children. Sinusitis has an incidence of 15–40 episodes per 1,000 patients annually, according to studies, and accounts for 0.5% of all upper respiratory tract infections. Additionally, general practitioners identify acute sinusitis as the second most typical infectious condition. Nearly 35 million Americans suffer from acute sinusitis, which is more common among elderly persons (45 to 64 years of age), according to a WebMD LLC. (US) article from February 2021.

Acute sinusitis causes more than 15 million patients to visit doctors each year in the US. Furthermore, acute sinusitis has a yearly frequency of 6-15% around the world, according to the World Allergy Organisation. Therefore, it is anticipated that throughout the projected period, the rising incidence of acute sinusitis cases will propel the expansion of the  acute sinusitis market CAGR.

It is projected that a rising  trend in healthcare research and development expenditures will support market growth in the future. One of the main trends in the acute sinusitis industry is the emergence of biologics. Right now, omalizumab is the best solution. This drug has been approved for the treatment of severe allergic asthma in both the US and Europe. Omalizumab is being tested by researchers for its safety and effectiveness in treating chronic rhinosinusitis with nasal polyps. The  acute sinusitis market is predicted to grow as a result of the successful introduction of biologics like omalizumab.

Key firms across the globe are continuously increasing their spending on marketing and innovation as a result of a continued focus on cost management and increased process efficiency. Thus, driving the acute sinusitis market revenue.

## **Acute Sinusitis Market Segment Insights**

### **Acute Sinusitis Treatment Insights**

The  acute sinusitis market segmentation, based on treatment includes Saline Nasal Spray, Nasal Corticosteroids, Decongestants, OTC Pain Relievers, Allergy Shots and Antibiotics. The antibiotics segment dominated the market. In order to prevent more severe complications from bacterial acute sinusitis affecting the frontal, sphenoid, or ethmoid sinuses, antibiotics are advised. For a very long time, antibiotics like macrolides, cephalosporins, and penicillins have been advised.

### **Acute Sinusitis End-Users Insights**

The  acute sinusitis market segmentation, based on end-users, includes Hospitals & Clinics and Research Centers. The hospitals & clinics category generated the most income following a large number of patients seeking sinus treatment at the hospitals & clinics. The category is predicted to grow as a result of the rising incidence of acute sinusitis and the favorable reimbursement requirements. The ability to perform sophisticated sinus surgeries, the presence of technologically advanced medical equipment, and the infrastructure will all encourage segment expansion.

**Figure 1  Acute Sinusitis Market, by End-Users, 2023 & 2032 (USD Billion)**

****

**_Source Secondary Research, Primary Research, MRFR Database and Analyst Review_**

### **Acute Sinusitis Diagnosis Insights**

The  acute sinusitis market segmentation, based on diagnosis, includes Nasal Endoscopy, Imaging Test, Laboratory Test and Allergy Testing. The nasal endoscopy category generated the most income. A nasal endoscope, a specialized tool used during rhinoscopy, is used to view the sinus apertures and nasal passageways. The nasal mucosa, any abnormal growths or polyps, and any indications of inflammation or illness can all be seen clearly. The diagnosis and evaluation of the severity of acute sinusitis are aided by nasal endoscopy.

### **Acute Sinusitis Regional Insights**

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American acute sinusitis market area will dominate this market. North America's growth is boosted by its technological advancements in diagnostic services, rising spending, and simple accessibility to healthcare facilities. The prevalence of chronic diseases in the US is rising, which is accelerating market expansion there. The CDC estimates that 11% of Americans have acute sinusitis. An alarming pace of growth is being observed in the occurrence of acute sinusitis.

The government and the manufacturers are collaborating to give better treatment options and are heavily investing in technical breakthroughs to address this issue. In the years to come, market expansion is also predicted to be fueled by rising consumer demand for over-the-counter drugs such decongestants, nasal sprays, and nasal corticosteroids.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure 2  ACUTE SINUSITIS MARKET SHARE BY REGION 2023 (USD Billion)**

****

**_Source Secondary Research, Primary Research, MRFR Database and Analyst Review_**

Europe acute sinusitis market accounts for the second-largest market share. The market is growing as a result of a well-established healthcare infrastructure and system, rising allergic rhinitis rates, and widespread product accessibility. The demand for its treatment is expected to rise due to the rising frequency of chronic sinusitis and the notable geographic variations in sinus-related disorders in European nations. Similarly, it is projected that the market will be similarly impacted by the rising prevalence of allergic rhinitis.

Approximately 20% of the population of Germany has at least one allergy, and only 10% of them choose to treat it properly, according to a study that was published in the World Allergy Organisation Journal. Further, the German acute sinusitis market held the largest market share, and the UK acute sinusitis market was the fastest growing market in the European region

The Asia-Pacific Acute sinusitis Market is expected to grow at the fastest CAGR from 2023 to 2032. Numerous acute and chronic diseases are becoming more commonplace at an alarming rate. India is home to 18% of the world's population with chronic respiratory disorders, according to the Institute for Health Metrics and Evaluation. Additionally, the market is expanding due to the growing demand for high-quality, affordable care. Aside from this, the region's simple access to treatment options and the rising number of people with sinusitis are fueling market expansion.

Moreover, China’s acute sinusitis market held the largest market share, and the Indian acute sinusitis market was the fastest growing market in the Asia-Pacific region.

**Acute Sinusitis Key Market Players & Competitive Insights**

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the acute sinusitis market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, acute sinusitis industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the  acute sinusitis industry to benefit clients and increase the market sector. In recent years, the acute sinusitis industry has offered some of the most significant advantages to market. Major players in the acute sinusitis market attempting to increase market demand by investing in research and development operations include Sanofi (France), Abbott (US), Bayer AG (Germany), Aurobindo Pharma (India), Bristol Myers Squibb (US), Merck KGaA (Germany), AstraZeneca (UK), Dr. Reddy’s Laboratories Ltd (India), Novartis AG (Switzerland), GlaxoSmithKline plc (UK) and Others.

Sanofi is a healthcare organisation that is involved in the development, production, marketing, and discovery of numerous drugs and vaccines. Its product line also includes human vaccinations for defence against a number of bacterial and viral infections, medications for the treatment of cancer, uncommon disorders, and multiple sclerosis, and other goods. Additionally, the company sells consumer healthcare items for women's health, digestion, allergy, cough, cold, flu, and sinuses, pain, and vitamins, minerals, and supplements. Sanofi's research and development efforts are concentrated on developing a combination therapy to boost treatment efficacy and on developing innovative biologic formulations to create precision medicines.

The healthcare corporation Novartis AG specializes in the development, production, and marketing of pharmaceutical goods for prescription and over-the-counter use as well as products for eye care. It offers medications for the treatment of ailments such infections, hematologic diseases, solid tumors, cancer, cardiovascular disease, dermatological issues, neurological disorders, ophthalmic and respiratory diseases, and others. Through Sandoz, the business sells biosimilars and generic medications. In August 2020, intranasal corticosteroids and Xolair have been approved by Novartis AG for the treatment of rhinosinusitis with nasal polyps.

**Key Companies in the acute sinusitis market include**

**Acute Sinusitis Industry Developments**

**_February 2022 _**_Olympus, a leader in developing and distributing ground-breaking solutions for medical and surgical procedures, declared that their CELERISTM single-use sinus debride system has been approved by the FDA and will soon be offered for purchase. In general ENT and sinus/rhinology procedures, the CELERIS system is made to cut, coagulate, debride, and remove thin bone and soft tissue._

**_August 2021 _**_When intranasal corticosteroids (INC) alone are not sufficient to address severe chronic rhinosinusitis with nasal polyps in patients 18 years of age and older, the European Commission (EC) has approved the use of Xolair (omalizumab) as an adjunctive therapy._

**_July 2021 _**_The Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as a treatment for people with chronic rhinosinusitis and nasal polyps, according to GlaxoSmithKline (GSK). This is a new indication for the interleukin-5 (IL-5)-targeting monoclonal antibody mepolizumab._

## **Acute Sinusitis Market Segmentation**

### **Acute Sinusitis Treatment Outlook (USD Billion, 2018-2032)**

### **Acute Sinusitis End Users Outlook (USD Billion, 2018-2032)**

### **Acute Sinusitis Diagnosis Outlook (USD Billion, 2018-2032)**

### **Acute Sinusitis Regional Outlook (USD Billion, 2018-2032)**

## Market Drivers

### Increase in Healthcare Expenditure

The upward trend in healthcare expenditure across various regions is likely to bolster The Global Acute Sinusitis Industry. As governments and private entities allocate more resources to healthcare, access to medical services and treatments improves. This increase in funding can lead to enhanced healthcare infrastructure, better diagnostic facilities, and more effective treatment options for acute sinusitis. Market data suggests that regions with higher healthcare spending tend to report better health outcomes, including lower rates of untreated sinusitis cases. Consequently, as healthcare expenditure continues to rise, it is anticipated that the market for acute sinusitis treatments will experience significant growth, driven by improved access to care and innovative treatment modalities.

### Expansion of Pharmaceutical Offerings

The expansion of pharmaceutical offerings specifically targeting acute sinusitis is poised to drive The Global Acute Sinusitis Industry. With ongoing research and development efforts, pharmaceutical companies are increasingly focusing on creating new medications that address the underlying causes of sinusitis. This includes the development of novel [antibiotics](https://www.marketresearchfuture.com/reports/antibiotics-market-8447), anti-inflammatory agents, and nasal sprays that aim to provide effective relief from symptoms. Market data indicates that the introduction of these new products is likely to enhance treatment options available to patients, thereby increasing overall market demand. As more effective and targeted therapies become available, healthcare providers will have a broader array of tools to manage acute sinusitis, potentially leading to improved patient outcomes and satisfaction.

### Rising Awareness of Sinusitis Symptoms

The increasing awareness regarding the symptoms and complications associated with sinusitis appears to be a pivotal driver for The Global Acute Sinusitis Industry. As individuals become more informed about the condition, they are more likely to seek medical attention, leading to a higher diagnosis rate. This heightened awareness is supported by various health campaigns and educational initiatives that aim to inform the public about sinusitis. Consequently, the demand for effective treatment options is likely to rise, thereby propelling market growth. Furthermore, the prevalence of acute sinusitis is estimated to affect millions globally, with a significant portion of the population experiencing recurrent episodes. This trend suggests that as awareness continues to grow, the market for acute sinusitis treatments will expand correspondingly.

### Technological Innovations in Diagnostic Tools

Technological advancements in diagnostic tools are likely to play a crucial role in shaping The Global Acute Sinusitis Industry. Innovations such as advanced imaging techniques and point-of-care testing are enhancing the accuracy and speed of sinusitis diagnosis. These developments not only facilitate timely treatment but also improve patient outcomes. For instance, the introduction of portable imaging devices allows healthcare providers to diagnose sinusitis more efficiently, potentially increasing patient throughput in clinical settings. As diagnostic accuracy improves, it is anticipated that more individuals will be diagnosed and treated for acute sinusitis, thereby driving market growth. The integration of artificial intelligence in diagnostic processes may further streamline operations, making it easier for healthcare professionals to identify and manage sinusitis cases.

### Growing Demand for Minimally Invasive Treatments

The rising preference for minimally invasive treatment options is emerging as a significant driver for The Global Acute Sinusitis Industry. Patients increasingly favor treatments that offer reduced recovery times and lower risks of complications. This trend is evident in the growing adoption of procedures such as balloon sinuplasty, which has gained popularity due to its effectiveness and minimal invasiveness. Market data indicates that the demand for such procedures is on the rise, as they provide a viable alternative to traditional surgical methods. As healthcare providers continue to adopt these innovative techniques, the market for acute sinusitis treatments is expected to expand. This shift towards less invasive options aligns with broader trends in healthcare, where patient-centric approaches are becoming increasingly prioritized.

## Future Outlook

The Global Acute Sinusitis Market is projected to grow at a 6.92% CAGR from 2025 to 2035, driven by increasing prevalence, advancements in treatment options, and rising healthcare expenditure.

**New opportunities:**

- Development of telehealth platforms for remote consultations and prescriptions. Investment in innovative drug delivery systems for enhanced patient compliance. Expansion of targeted marketing strategies to raise awareness among at-risk populations.

By 2035, the market is expected to achieve substantial growth, reflecting evolving healthcare dynamics.

## Segment Insights

### By Treatment: Nasal Corticosteroids (Largest) vs. Saline Nasal Spray (Fastest-Growing)

In The Global Acute Sinusitis Market, the treatment segment showcases varied market share distribution across several key products. Nasal [Corticosteroids](https://www.marketresearchfuture.com/reports/corticosteroids-market-43141)currently hold the largest share due to their effectiveness in reducing inflammation and alleviating symptoms, making them a preferred choice among healthcare providers. In contrast, Saline Nasal Spray is emerging as a fast-growing alternative, favored for its non-pharmacological benefits and safety profile, leading to an increase in consumer preference for natural treatments. Growth trends in this segment are influenced by rising awareness about sinusitis management and the increasing preference for over-the-counter solutions that provide symptomatic relief. As patients seek quicker access to treatments, products like decongestants and OTC pain relievers are gaining traction. Additionally, the introduction of innovative formulations and combination therapies is anticipated to further propel growth in this segment, addressing both the symptomatic and underlying causes of acute sinusitis.

Nasal Corticosteroids (Dominant) vs. Saline Nasal Spray (Emerging)

Nasal Corticosteroids are considered the dominant treatment option in The Global Acute Sinusitis Market due to their potent anti-inflammatory properties and clinical efficacy in managing sinusitis symptoms. These corticosteroids help in reducing nasal obstruction and improving overall sinus function, making them a staple in treatment protocols. On the other hand, Saline Nasal Spray is positioned as an emerging product, gaining popularity for its gentle approach to nasal care. Increasingly, patients are opting for saline sprays as they provide a natural way to moisturize nasal passages and flush out irritants without the side effects associated with pharmaceuticals. Both treatments address different patient needs, with corticosteroids catering to those requiring stronger symptom management, while saline sprays appeal to consumers prioritizing holistic approaches.

### By End-Users: Hospitals (Largest) vs. Research Centers (Fastest-Growing)

In The Global Acute Sinusitis Market, hospitals emerge as the largest end-users, significantly dominating the sector due to their high patient volume and comprehensive care facilities. Their ability to provide specialized treatment and wide-ranging resources allows hospitals to capture a substantial market share, making them a key player in managing acute sinusitis cases. On the other hand, research centers are gaining traction, driven by their focus on innovative treatments and therapies, positioning them as critical players in shaping future market dynamics. As the awareness of acute sinusitis and its treatment options increases, both hospitals and research centers are experiencing unique growth trends. Hospitals are expanding their facilities and staff to meet the rising demand for sinusitis care, while research centers are leveraging advancements in technology and clinical research to spearhead new treatment protocols. This dual focus contributes to a supportive ecosystem where both types of end-users can thrive, although each approaches the market from different strategic viewpoints.

Hospitals (Dominant) vs. Research Centers (Emerging)

Hospitals serve as the dominant end-user segment in The Global Acute Sinusitis Market, offering comprehensive care and specialized services that cater to a large patient demographic. Their extensive resources and multi-disciplinary teams enable them to manage complex sinusitis cases effectively, also fostering collaborations with specialists in otolaryngology and allergy medicine. Conversely, research centers represent the emerging segment within this landscape, committed to innovation and the development of new therapeutic strategies. These centers focus on clinical trials and the formulation of breakthrough treatments, often aligning with hospitals and pharmaceutical companies to bring these innovations to market quickly. The interplay between hospitals’ established infrastructure and research centers’ innovative approaches creates a dynamic environment for growth and advancement in acute sinusitis management.

### By Diagnosis: Nasal Endoscopy (Largest) vs. Imaging Test (Fastest-Growing)

The Global Acute Sinusitis Market showcases a diverse range of diagnostic methods, with Nasal Endoscopy currently holding the largest market share. This technique enables direct visualization of the nasal cavity and sinuses, allowing for accurate diagnosis. Imaging Tests, particularly CT and MRI scans, follow as significant contributors while maintaining a steady share of the market. Laboratory Tests and Allergy Testing also play vital roles, albeit with smaller proportions in comparison. Growth in this segment is primarily driven by increasing awareness regarding chronic sinusitis and improvements in diagnostic technologies. Nasal Endoscopy remains a staple due to its efficacy and precision, while Imaging Tests are rapidly gaining traction as advancements in imaging technology enable quicker, non-invasive evaluations. The demand for accurate and timely diagnosis is shifting market dynamics favorably towards these methods.

Nasal Endoscopy: Dominant vs. Allergy Testing: Emerging

Nasal Endoscopy, as the dominant diagnostic method in The Global Acute Sinusitis Market, offers comprehensive insights into the sinus anatomy, making it a preferred choice among physicians. It is particularly valuable for patients with recurrent symptoms, providing immediate results that can guide further management. On the other hand, Allergy Testing is emerging as a crucial segment, identifying allergic triggers that may exacerbate sinusitis symptoms. This approach not only supports sinusitis diagnosis but also extends to personalized treatment plans for patients. The interaction of these two diagnostic tools highlights the evolving landscape of acute sinusitis management, where comprehensive evaluations pave the way for improved patient outcomes.

## Regional Market Share Analysis

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American acute sinusitis market area will dominate this market. North America's growth is boosted by its technological advancements in diagnostic services, rising spending, and simple accessibility to healthcare facilities. The prevalence of chronic diseases in the US is rising, which is accelerating market expansion there. The CDC estimates that 11% of Americans have acute sinusitis. An alarming pace of growth is being observed in the occurrence of acute sinusitis.

The government and the manufacturers are collaborating to give better treatment options and are heavily investing in technical breakthroughs to address this issue. In the years to come, market expansion is also predicted to be fueled by rising consumer demand for over-the-counter drugs such [decongestants](https://www.marketresearchfuture.com/reports/decongestant-market-59664), nasal sprays, and nasal corticosteroids.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure 2  ACUTE SINUSITIS MARKET SHARE BY REGION 2023 (USD Billion)**

**_Source Secondary Research, Primary Research, MRFR Database and Analyst Review_**

Europe acute sinusitis market accounts for the second-largest market share. The market is growing as a result of a well-established healthcare infrastructure and system, rising allergic rhinitis rates, and widespread product accessibility. The demand for its treatment is expected to rise due to the rising frequency of chronic sinusitis and the notable geographic variations in sinus-related disorders in European nations. Similarly, it is projected that the market will be similarly impacted by the rising prevalence of allergic rhinitis.

Approximately 20% of the population of Germany has at least one allergy, and only 10% of them choose to treat it properly, according to a study that was published in the World Allergy Organisation Journal. Further, the German acute sinusitis market held the largest market share, and the UK acute sinusitis market was the fastest growing market in the European region

The Asia-Pacific Acute sinusitis Market is expected to grow at the fastest CAGR from 2023 to 2032. Numerous acute and chronic diseases are becoming more commonplace at an alarming rate. India is home to 18% of the world's population with chronic respiratory disorders, according to the Institute for Health Metrics and Evaluation. Additionally, the market is expanding due to the growing demand for high-quality, affordable care. Aside from this, the region's simple access to treatment options and the rising number of people with sinusitis are fueling market expansion.

Moreover, China’s acute sinusitis market held the largest market share, and the Indian acute sinusitis market was the fastest growing market in the Asia-Pacific region.

## Competitive Benchmarking

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the acute sinusitis market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, acute sinusitis industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the  acute sinusitis industry to benefit clients and increase the market sector. In recent years, the acute sinusitis industry has offered some of the most significant advantages to market. Major players in the acute sinusitis market attempting to increase market demand by investing in research and development operations include Sanofi (France), Abbott (US), Bayer AG (Germany), Aurobindo Pharma (India), Bristol Myers Squibb (US), Merck KGaA (Germany), AstraZeneca (UK), Dr. Reddy’s Laboratories Ltd (India), Novartis AG (Switzerland), GlaxoSmithKline plc (UK) and Others.
Sanofi is a healthcare organisation that is involved in the development, production, marketing, and discovery of numerous drugs and vaccines. Its product line also includes human vaccinations for defence against a number of bacterial and viral infections, medications for the treatment of cancer, uncommon disorders, and multiple sclerosis, and other goods. Additionally, the company sells consumer healthcare items for women's health, digestion, allergy, cough, cold, flu, and sinuses, pain, and vitamins, minerals, and supplements. Sanofi's research and development efforts are concentrated on developing a combination therapy to boost treatment efficacy and on developing innovative biologic formulations to create precision medicines.
The healthcare corporation Novartis AG specializes in the development, production, and marketing of pharmaceutical goods for prescription and over-the-counter use as well as products for eye care. It offers medications for the treatment of ailments such infections, hematologic diseases, solid tumors, cancer, cardiovascular disease, dermatological issues, neurological disorders, ophthalmic and respiratory diseases, and others. Through Sandoz, the business sells biosimilars and generic medications.
In August intranasal corticosteroids and Xolair have been approved by Novartis AG for the treatment of rhinosinusitis with nasal polyps.

## Recent News & Developments

**_February 2022 _**_Olympus, a leader in developing and distributing ground-breaking solutions for medical and surgical procedures, declared that their CELERISTM single-use sinus debride system has been approved by the FDA and will soon be offered for purchase. In general ENT and sinus/rhinology procedures, the CELERIS system is made to cut, coagulate, debride, and remove thin bone and soft tissue._

**_August 2021 _**_When intranasal corticosteroids (INC) alone are not sufficient to address severe chronic rhinosinusitis with nasal polyps in patients 18 years of age and older, the European Commission (EC) has approved the use of Xolair (omalizumab) as an adjunctive therapy._

**_July 2021 _**_The Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as a treatment for people with chronic rhinosinusitis and nasal polyps, according to GlaxoSmithKline (GSK). This is a new indication for the interleukin-5 (IL-5)-targeting monoclonal antibody mepolizumab._

## Report Scope

| MARKET SIZE 2024 | 2.319(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 2.48(USD Billion) |
| MARKET SIZE 2035 | 4.842(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.92% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | GlaxoSmithKline (GB), Sanofi (FR), Bayer (DE), Merck & Co. (US), AstraZeneca (GB), Novartis (CH), Teva Pharmaceutical Industries (IL), Johnson & Johnson (US), AbbVie (US) |
| Segments Covered | Treatment, End-Users, Diagnosis, Region |
| Key Market Opportunities | Advancements in telemedicine enhance access to treatment for The Global Acute Sinusitis. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition and influences treatment protocols in the acute sinusitis market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation of The Global Acute Sinusitis by 2035?**
A: The projected market valuation for The Global Acute Sinusitis is 4.842 USD Billion by 2035.

**Q: What was the market valuation of The Global Acute Sinusitis in 2024?**
A: The overall market valuation was 2.319 USD Billion in 2024.

**Q: What is the expected CAGR for The Global Acute Sinusitis during the forecast period 2025 - 2035?**
A: The expected CAGR for The Global Acute Sinusitis during the forecast period 2025 - 2035 is 6.92%.

**Q: Which companies are considered key players in The Global Acute Sinusitis?**
A: Key players in the market include GlaxoSmithKline, Sanofi, Bayer, Merck & Co., AstraZeneca, Novartis, Teva Pharmaceutical Industries, Johnson & Johnson, and AbbVie.

**Q: What segment generated the highest revenue in the treatment category for The Global Acute Sinusitis?**
A: In the treatment category, Nasal Corticosteroids generated the highest revenue, with a valuation of 1.442 USD Billion projected.

**Q: How much is the Hospitals & Clinics segment expected to be valued at by 2035?**
A: The Hospitals & Clinics segment is expected to reach a valuation of 2.883 USD Billion by 2035.

**Q: What is the projected valuation for the Allergy Testing segment by 2035?**
A: The Allergy Testing segment is projected to be valued at 1.042 USD Billion by 2035.

**Q: What is the expected growth trend for the Decongestants segment in The Global Acute Sinusitis?**
A: The Decongestants segment is expected to grow, with a projected valuation of 0.964 USD Billion by 2035.

**Q: What is the anticipated market performance for Imaging Tests in the diagnosis segment?**
A: The Imaging Test segment is anticipated to reach a valuation of 1.2 USD Billion by 2035.

**Q: How does the revenue from Antibiotics compare to other treatment options in the market?**
A: The revenue from Antibiotics is projected to be lower than other treatment options, with a valuation of 0.242 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/acute-sinusitis-market-5827*